← Back to patent-cliff list
BN-104
Tier C — Watch / tradeBN-104
-
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：MEN1
Indications (approved)：Leukaemia, Acute myeloid leukaemia, Acute lymphoblastic leukaemia, 双表型急性白血病, Haematological malignancy
Regional status
US
Phase I
2023-09-21
EU
-
China
Phase II
2023-10-19
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of BN-104?
Approved indications include: Leukaemia, Acute myeloid leukaemia, Acute lymphoblastic leukaemia, 双表型急性白血病, Haematological malignancy.
When does the BN-104 patent expire?
No public expiry year is available for BN-104 yet; this page updates once verified.
How do I get a quote for BN-104 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-02